Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Leblebicioglu H., Arends J. E., Ozaras R., Corti G., Santos L., Boesecke C., ...More

ANTIVIRAL RESEARCH, vol.150, pp.9-14, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 150
  • Publication Date: 2018
  • Doi Number: 10.1016/j.antiviral.2017.12.001
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.9-14
  • Istanbul University Affiliated: Yes


Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries.